DR. KARL YODER HOSTETLER, M.D.
Osteopathic Medicine in San Diego, CA
License number
California C32005
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California C32005
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
2
200 W Arbor Dr Ucsd Medical Ctr, San Diego, CA 92103
14024 Rue Saint Raphael, Del Mar, CA 92014
14024 Rue Saint Raphael, Del Mar, CA 92014
Phone
(858) 657-8440
(619) 543-3183 (Fax)
(858) 755-7503
(858) 755-6095 (Fax)
(619) 543-3183 (Fax)
(858) 755-7503
(858) 755-6095 (Fax)
Personal information
See more information about KARL YODER HOSTETLER at radaris.comName
Address
Phone
14024 Rue Saint Raphael, Del Mar, CA 92014
1406 Armsley Sq, Ontario, CA 91762
14024 Rue Saint Raphael, Del Mar, CA 92014
13312 Pantera Rd, San Diego, CA 92130
1406 Armsley Sq, Ontario, CA 91762
Professional information
See more information about KARL YODER HOSTETLER at trustoria.com
Phosphonate Compounds
Phosphonate Compounds
US Patent:
6716825, Apr 6, 2004
Filed:
Nov 6, 2002
Appl. No.:
10/148374
Inventors:
Karl Y. Hostetler - Del Mar CA
James R. Beadle - San Diego CA
Ganesh D. Kini - Bristow VA
James R. Beadle - San Diego CA
Ganesh D. Kini - Bristow VA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07H 1900
US Classification:
514 52, 514 75, 568 8, 435 11
Abstract:
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorder, e. g. , osteoporosis and other disorders of bone metabolisum, cancer, viral infections, and the like.
Lipid Derivatives Of Phosphonoacids For Liposomal Incorporation And Method Of Use
Lipid Derivatives Of Phosphonoacids For Liposomal Incorporation And Method Of Use
US Patent:
5744461, Apr 28, 1998
Filed:
May 26, 1995
Appl. No.:
8/451221
Inventors:
Karl Y. Hostetler - Del Mar CA
Raj Kumar - San Diego CA
Raj Kumar - San Diego CA
Assignee:
NeXstar Pharmaceuticals, Inc. - Boulder CO
International Classification:
A01N 5718
US Classification:
514141
Abstract:
Lipid-containing prodrugs are provided for treating viral infections due to herpes, influenza, hepatitis B, Epstein-Barr, and varicella zoster viruses, as well as cytomegalovirus and derivatives of antiviral agents. The compounds comprise phosphonoacids having antiviral activity which are linked, either through the phosphate group or carboxyl group of the phosphonoacid, to one of a selected group of lipids. Phosphonoacetic acid and phosphonoformic acid are thus linked to phospholipids, glycerolipids, sphingolipids, glycolipids, or fatty acids. The compounds persist, after intracellular hydrolysis, as the antiviral phosphonoacids. The lipid prodrugs are effective in improving the efficacy of antiviral phosphonoacids by prolonging their antiviral activity following administration.
Prodrugs For Oral Administration Containing Taxol Or Substituted Taxol Covalently Bound To A Phospholipid
Prodrugs For Oral Administration Containing Taxol Or Substituted Taxol Covalently Bound To A Phospholipid
US Patent:
5484809, Jan 16, 1996
Filed:
Dec 14, 1994
Appl. No.:
8/355510
Inventors:
Karl Y. Hostetler - Del Mar CA
Nagarajan C. Sridhar - Simi Valley CA
Nagarajan C. Sridhar - Simi Valley CA
Assignee:
Vestar, Inc. - San Dimas CA
International Classification:
A01N 4302, A01N 4304, C07D30700, C07D30500
US Classification:
514449
Abstract:
The oral delivery of many classes of drugs is facilitated by converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives. The method confers the ability to be absorbed through the digestive tract to drugs that are not orally bioavailable in the non-derivatized state, and enhances the effectiveness of drugs that are poorly absorbed or rapidly eliminated. The method provides orally bioavailable lipid prodrugs of zaxol and taxol-related compounds. Potency of the lipid prodrugs is comparable to that of the corresponding nonderivatized drugs. In a preferred embodiment, taxol or substituted taxol is covalently bound to a phospholipid.
Lipid Conjugates Of Therapeutic Peptides And Protease Inhibitors
Lipid Conjugates Of Therapeutic Peptides And Protease Inhibitors
US Patent:
5554728, Sep 10, 1996
Filed:
Jul 23, 1991
Appl. No.:
7/734434
Inventors:
Channa Basava - San Diego CA
Karl Y. Hostetler - Del Mar CA
Karl Y. Hostetler - Del Mar CA
Assignee:
NeXstar Pharmaceuticals, Inc. - Boulder CO
International Classification:
C07K 500, C07K 700, C07K 1700, A61K 3800
US Classification:
530327
Abstract:
Compounds wherein therapeutic peptides are covalently linked to phospholipids, glycerides or other membrane-targeting and membrane-anchoring species, and their pharmaceutically acceptable salts, together with processes for their preparation. The targeting technology is applicable to HIV protease inhibitors and a variety of other enzyme inhibitors.
Lipid Nucleotide Analog Prodrugs For Oral Administration
Lipid Nucleotide Analog Prodrugs For Oral Administration
US Patent:
5827831, Oct 27, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/484018
Inventors:
Karl Y. Hostetler - Del Mar CA
Raj Kumar - San Diego CA
Nagarajan C. Sridhar - Simi Valley CA
Raj Kumar - San Diego CA
Nagarajan C. Sridhar - Simi Valley CA
Assignee:
NeXstar Pharmaceuticals, Inc. - Boulder CO
International Classification:
A61K 3170
US Classification:
514 47
Abstract:
The oral delivery of many classes of drugs is facilitated by converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn- glycero-3-phosphate derivatives. The method confers the ability to be absorbed through the digestive tract to drugs that are not orally bioavailable in the non-derivatized state, and enhances the effectiveness of drugs that are poorly absorbed or rapidly eliminated. The method provides orally bioavailable lipid prodrugs of pharmaceutical compounds having diverse physiological activities, including anticancer and antiviral agents, anti-inflammatory agents, antihypertensives and antibiotics. Potency of the lipid prodrugs is comparable to that of the corresponding non-derivatized drugs.
Synthetic Calcitonin Peptides
Synthetic Calcitonin Peptides
US Patent:
5364840, Nov 15, 1994
Filed:
Jun 5, 1991
Appl. No.:
7/711180
Inventors:
Channa Basava - San Diego CA
Karl Y. Hostetler - Del Mar CA
Karl Y. Hostetler - Del Mar CA
Assignee:
Vical, Inc. - San Diego CA
International Classification:
A61K 3700, A61K 3702, A61K 3730, C07K 500
US Classification:
514 12
Abstract:
Synthetic hypocalcemic peptides which are superior in biological properties to native calcitonins as clinically useful agents. The peptides comprise analogues of native calcitonins having amino acid additions at the N-terminal position which, either alone or together with substitutions, and deletions at other residues, act to improve potency, prolong duration of the hormonal effect, and increase oral or nasal bioavailability. Methods are provided for the synthesis of these peptides.
Phosphonate Compounds
Phosphonate Compounds
US Patent:
7094772, Aug 22, 2006
Filed:
Apr 6, 2005
Appl. No.:
11/100882
Inventors:
Karl Y. Hostetler - Del Mar CA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/662, C07D 239/02, C07D 473/00
US Classification:
514110, 544264, 544317, 558 85, 261274
Abstract:
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e. g. , osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.
Phosphonate Compounds
Phosphonate Compounds
US Patent:
7034014, Apr 25, 2006
Filed:
Jan 15, 2004
Appl. No.:
10/759345
Inventors:
Karl Y. Hostetler - Del Mar CA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/52, A61K 31/505, A61K 31/665, C07D 239/22, C07D 473/00
US Classification:
514110, 261274, 544264, 544317, 558 85
Abstract:
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e. g. , osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.
Phosphonate Compounds
Phosphonate Compounds
US Patent:
8008308, Aug 30, 2011
Filed:
Feb 5, 2010
Appl. No.:
12/701410
Inventors:
Karl Y. Hostetler - Del Mar CA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/52, C07C 9/02
US Classification:
514261, 544244
Abstract:
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e. g. , osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.
Phosphonate Compounds
Phosphonate Compounds
US Patent:
7790703, Sep 7, 2010
Filed:
Mar 7, 2007
Appl. No.:
11/715604
Inventors:
Karl Y. Hostetler - Del Mar CA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
James R. Beadle - San Diego CA, US
Ganesh D. Kini - Bristow VA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/52, A61K 31/505, A61K 31/665, C07D 239/22, C07D 473/00
US Classification:
514110, 544264, 544317
Abstract:
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e. g. , osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.